Return to search

Novel bioactive secondary metabolites from the marine cyanobacterium Lyngbya majuscula

Marine algae have been recognized as a rich resource of new
and unusual organic molecules with diverse biological properties.
The current need to develop new antifungal, anticancer, antibiotic
and antiviral drugs has led to an intense research effort into the
discovery, isolation and structure determination of potential
medicinal agents from marine algae.
In the past two years, I have participated in a drug discovery
program designed for antitumor, antifungal and other agents of
potential pharmaceutical utility from the marine cyanobacterium
Lyngbya majuscula. This research utilized modern chromatographic
and spectrochemical techniques including 2D NMR spectroscopy.
Brine shrimp toxicity guided the fractionation that led to the
discovery of the biologically active compound kalkitoxin from a
Curacao Lyngbya majuscula extract. The structure of this new
thiazoline ring-containing lipid was determined spectroscopically
by interpretation of 2D-NMR experiments, including heteronuclear
multiple quantum coherence (HMQC), heteronuclear multiple-bond
coherence spectroscopy (HMBC) and ��H-��H COSY at room
temperature and elevated temperature. Kalkitoxin shows modest
molluscicidal toxicity, good brine shrimp toxicity and extremely
potent ichthyotoxicity.
From the same extract of Lyngbya majuscula, I also isolated
two other secondary metabolites, malyngamide J and malyngamide
L. The structures of these new compounds, including
stereochemistry, were determined by spectroscopic techniques
including 2D-NMR experiments and by comparison with other
known malyngamides. / Graduation date: 1997
Date13 September 1996
CreatorsWu, Min, 1963-
ContributorsGerwick, William H.
Source SetsOregon State University
Detected LanguageEnglish

Page generated in 0.0022 seconds